TrialThe lancet. HIV2026

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

Esteban Martínez et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT02344290. The trial’s primary report, PMID 37486775, speaks for it on the map; the numbers here are shown and do not vote.

Pitavastatinlooks good hereLower hypertension.Randomised, large.

What the trial testedrandomised · 7,769 people · 2026

Randomised vs placebo

Lowered hypertension

Doesn’t vote: a later paper about the trial

−17%−29% to −3%

pitavastatin vs placebo

Bigger than 4 in 10 on the map

As reported

HR 0.83, 95% CI 0.71–0.97 · the paper's word: incidence of hypertension

Who was studied, and how

7,769people with hypertension, in this paper

The trial randomly assignedassigned by chance

pitavastatin

placebo

Lowered hypertension−17%

randomised

the abstract, start to end

… (cause-specific hazard ratio [HR] 0.83, 95% CI 0.71-0.97; p=0.017).

← favours treatmentfavours comparator →

could be chance

Incidence of hypertensionpitavastatin vs placebo

HR 0.830.71–0.97

StatinsBlood pressure

1 / 4

2 papers cite it

2026

this papertrialcites it

The trial

NCT02344290phase 37,769 enrolled2015a later paper about it

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

What the trial testedrandomised · 7,769 people · 2026

Lowered hypertension

Who was studied, and how

One number in the abstract

Where each one falls

Where it lands on the map

2 papers cite it

The trial